Healthcare of Ontario Pension Plan Trust Fund Makes New Investment in Alimera Sciences, Inc. (NASDAQ:ALIM)

Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Alimera Sciences, Inc. (NASDAQ:ALIMGet Rating) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 250,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,400,000. Healthcare of Ontario Pension Plan Trust Fund owned approximately 3.58% of Alimera Sciences at the end of the most recent quarter.

Analysts Set New Price Targets

Several research analysts have commented on the company. HC Wainwright boosted their target price on Alimera Sciences from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, July 28th. StockNews.com started coverage on Alimera Sciences in a research note on Friday, September 2nd. They set a “hold” rating for the company.

Alimera Sciences Trading Up 5.5 %

Alimera Sciences stock opened at $6.88 on Thursday. The company has a market capitalization of $48.13 million, a PE ratio of -2.76 and a beta of 1.32. Alimera Sciences, Inc. has a 12 month low of $3.94 and a 12 month high of $7.92. The stock has a 50-day moving average price of $6.19 and a two-hundred day moving average price of $5.69.

Alimera Sciences (NASDAQ:ALIMGet Rating) last posted its earnings results on Wednesday, July 27th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.16. During the same period in the prior year, the company earned $0.76 earnings per share. As a group, analysts predict that Alimera Sciences, Inc. will post -1.85 earnings per share for the current fiscal year.

Alimera Sciences Company Profile

(Get Rating)

Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

Featured Articles

Institutional Ownership by Quarter for Alimera Sciences (NASDAQ:ALIM)

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.